stockportfolio.pro
Stocks / GLUE vs SEPN
GLUE vs SEPN
Monte Rosa Therapeutics, Inc. and Septerna, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Monte Rosa Therapeutics, Inc. (GLUE) | Septerna, Inc. (SEPN) | |
|---|---|---|
| Market cap | $1.5B | $1.5B |
| Revenue (latest FY) | $123.67M | $45.95M |
| Net income (latest FY) | $-38.63M | $-48.88M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | -31.2% | -106.4% |
| Return on equity | -16.6% | -12.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open GLUE — free Open SEPN — freeFrequently asked questions
Which is bigger, GLUE or SEPN?
Septerna, Inc. is larger by market capitalization — $1.5B versus $1.5B.
Which grows faster, GLUE or SEPN?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.